# Brooks Laboratories (NSE: BROOKS) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/BROOKS · Pivot · prices to 22 Oct 2026

Brooks Laboratories (NSE: BROOKS) closed at ₹63.12 on 22 Oct 2026, up 4.31% on the day. With a market capitalisation of ₹186 Cr, it ranks 2312th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 7.6× trailing earnings, against a return on equity of −10.2% in FY25. Over the past year the share price has fallen 49.8%. Its 52-week range is ₹36.30 (30 Mar 2026) to ₹123.54 (23 Oct 2025); the last close is 48.9% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹20 Cr (−13.3% year on year) and net profit ₹1 Cr (−54.5%), on a consolidated basis. Promoters held 52.62% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹63.12 |
| Market cap | ₹186 Cr |
| P/E (trailing) | 7.6 |
| ROE | −10.2% (FY25) |
| ROCE | 4.2% (FY25) |
| Debt to equity | 0.06 |
| 52-week high | ₹123.54 (23 Oct 2025) |
| 52-week low | ₹36.30 (30 Mar 2026) |
| 1-year return | −49.8% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹20 Cr | −13.3% | ₹1 Cr | −54.5% | ₹0.52 |
| Q3 FY26 | ₹17 Cr | −56.9% | ₹0 Cr | −57.1% | ₹1.87 |
| Q2 FY26 | ₹23 Cr | +12.8% | ₹2 Cr | +133.3% | ₹2.71 |
| Q1 FY26 | ₹26 Cr | +42.3% | ₹3 Cr | — | ₹3.25 |
| Q4 FY25 | ₹23 Cr | +31.6% | ₹1 Cr | +346.7% | −₹0.54 |
| Q3 FY25 | ₹38 Cr | +76.8% | ₹1 Cr | +20.7% | −₹1.75 |
| Q2 FY25 | ₹21 Cr | −14.5% | ₹1 Cr | −18.6% | −₹1.51 |
| Q1 FY25 | ₹18 Cr | +14.2% | −₹0 Cr | — | −₹0.94 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹83 Cr | ₹3 Cr |
| FY24 | ₹79 Cr | ₹2 Cr |
| FY23 | ₹63 Cr | −₹28 Cr |
| FY22 | ₹91 Cr | −₹19 Cr |
| FY21 | ₹77 Cr | −₹19 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 52.62%
- Foreign institutions: 0.00%
- Domestic institutions: 10.38%
- Non-institutions: 37.00%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Coral Labs](https://app.pivotnow.in/stock/CORALAB) | — | ₹196 Cr | — | — |
| [Aashka Hospital](https://app.pivotnow.in/stock/AASHKA) | — | ₹190 Cr | — | — |
| [OXYGENTA PHARMA](https://app.pivotnow.in/stock/OXYGENTAPH) | — | ₹185 Cr | — | — |
| [Accretion Nutra](https://app.pivotnow.in/stock/ANL) | — | ₹184 Cr | — | — |
| [Earkart](https://app.pivotnow.in/stock/EARKART) | — | ₹182 Cr | — | — |
| [Novelix Pharma](https://app.pivotnow.in/stock/NOVELIX) | — | ₹181 Cr | — | — |

## Questions and answers

### What is the share price of Brooks Laboratories today?

Brooks Laboratories (NSE: BROOKS) last closed at ₹63.12 on 22 Oct 2026. Its 52-week high is ₹123.54 and its 52-week low is ₹36.30.

### What is the market cap of Brooks Laboratories?

Brooks Laboratories' market capitalisation is ₹186 Cr (₹186 Cr) at the 22 Oct 2026 close, ranking 2312th among the NSE companies Pivot tracks.

### What is the P/E ratio of Brooks Laboratories?

Brooks Laboratories trades at a trailing P/E of 7.6.

### What is the ROE and ROCE of Brooks Laboratories?

Return on equity was −10.2% in FY25 and return on capital employed was 4.2% in FY25 (consolidated figures).

### Is Brooks Laboratories a debt-free company?

No. Brooks Laboratories' debt-to-equity ratio was 0.06 in FY25, with total debt of ₹0 Cr.

### What were Brooks Laboratories' latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Brooks Laboratories reported revenue of ₹20 Cr, −13.3% year on year, and net profit of ₹1 Cr, −54.5% year on year.

### How has Brooks Laboratories stock performed over the last year?

Brooks Laboratories' share price has fallen 49.8% over the past year, −5.9% over three months and +6.8% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Brooks Laboratories?

As of 30 Jun 2026: promoters 52.62%, foreign institutions 0.00%, domestic institutions 10.38%, non-institutions 37.00%.

### Who are Brooks Laboratories' competitors?

The listed Pharma & Healthcare companies closest to Brooks Laboratories by market cap are Coral Labs, Aashka Hospital, OXYGENTA PHARMA, Accretion Nutra, Earkart and Novelix Pharma.

### Is Brooks Laboratories a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Brooks Laboratories' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on BROOKS against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.